1,707
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Targeting the superoxide/nitric oxide ratio by L-arginine and SOD mimic in diabetic rat skin

, , , , , , , & show all
Pages S51-S63 | Received 24 Jun 2016, Accepted 31 Aug 2016, Published online: 25 Oct 2016
 

Abstract

Setting the correct ratio of superoxide anion (O2•-) and nitric oxide (NO) radicals seems to be crucial in restoring disrupted redox signaling in diabetic skin and improvement of NO physiological action for prevention and treatment of skin injuries in diabetes. In this study we examined the effects of L-arginine and manganese(II)-pentaazamacrocyclic superoxide dismutase (SOD) mimic – M40403 in diabetic rat skin. Following induction of diabetes by alloxan (blood glucose level ≥12 mMol l −1) non-diabetic and diabetic male Mill Hill hybrid hooded rats were divided into three subgroups: (i) control, and receiving: (ii) L-arginine, (iii) M40403. Treatment of diabetic animals started after diabetes induction and lasted for 7 days. Compared to control, lower cutaneous immuno-expression of endothelial NO synthase (eNOS), heme oxygenase 1 (HO1), manganese SOD (MnSOD) and glutathione peroxidase (GSH-Px), in parallel with increased NFE2-related factor 2 (Nrf2) and nitrotyrosine levels characterized diabetic skin. L-arginine and M40403 treatments normalized alloxan-induced increase in nitrotyrosine. This was accompanied by the improvement/restitution of eNOS and HO1 or MnSOD and GSH-Px protein expression levels in diabetic skin following L-arginine, i.e. SOD mimic treatments, respectively. The results indicate that L-arginine and M40403 stabilize redox balance in diabetic skin and suggest the underlying molecular mechanisms. Restitution of skin redox balance by L-arginine and M40403 may represent an effective strategy to ameliorate therapy of diabetic skin.

Disclosure statement

The authors report no conflicts of interest.

Funding

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia [Grant No 173055] and the European Cooperation in Science and Research [COST Action CM1201].